Welcome to our dedicated page for Immunoprecise news (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on Immunoprecise stock.
The IPA news archive on Stock Titan covers ImmunoPrecise Antibodies Ltd. during its evolution into a bio-native AI and biotherapeutics platform business. Company press releases and related coverage describe how IPA operated at the intersection of TechBio and next-generation drug discovery, combining its LENSai™ platform and HYFT® multi-omics technology with wet-lab capabilities in biologics discovery, engineering, and characterization.
Readers can review news items detailing IPA’s financial results, including discussions of revenue trends, margins, and segment performance, as well as updates on strategic priorities such as focusing on AI-based product development. Coverage also includes corporate developments like the divestiture of ImmunoPrecise Antibodies (Europe) B.V. to AVS Bio, which the company framed as part of a strategic refinement to streamline operations and concentrate resources on its scientific platforms and data-driven discovery technologies.
Scientific and platform-related announcements form another key part of the IPA news flow. These include updates on the LENSai/HYFT platform’s capabilities in areas such as in silico epitope mapping, universal dengue vaccine candidate discovery, AI-designed GLP-1 peptides, and immunogenicity screening aimed at predicting anti-drug-antibody risk. The news stream also reflects corporate milestones like conference participation, advisory board appointments, and the company’s rebranding under the MindWalk name with a Nasdaq ticker change from IPA to HYFT.
For investors, researchers, and industry observers, this page serves as a historical record of ImmunoPrecise Antibodies’ public communications while it traded under the IPA symbol, including its transition toward the MindWalk brand and associated AI-native discovery platform.
ImmunoPrecise Antibodies (IPA) reported Q3 FY25 financial results, securing an $8-10M strategic partnership for co-developing Antibody-Drug Conjugates and bispecific antibodies. The company expanded AI infrastructure through collaborations with Vultr and GPU technology providers.
Key financial highlights include:
- Revenue remained stable at $6.2M
- BioStrand showed 131.8% YoY revenue growth with 97% gross margin
- Net loss of $21.5M ($0.66 per share) vs $2.7M loss in FY24 Q3
- Cash position of $12.9M as of January 31, 2025
Notable developments include headquarters relocation to Austin, Texas, completion of an $8.8M ATM equity raise, and full conversion of Yorkville debenture. The company recorded a $21.2M impairment charge related to BioStrand's intangible assets.
ImmunoPrecise Antibodies (NASDAQ: IPA) has entered into a strategic partnership with a leading biotechnology company to develop Antibody-Drug Conjugates (ADCs) and bispecific antibodies for cancer treatment. The collaboration, valued at $8 million with potential expansion to $10 million, will span 18-24 months.
The partnership integrates IPA's proprietary B-cell Select™ platform and AI-driven discovery capabilities to enhance therapeutic development efficiency. The scope includes discovery, lead characterization, optimization, and preclinical-grade production of multiple antibody-based therapeutics, focusing on developing highly selective cancer treatments.
The project combines IPA's multi-omics AI-driven modeling and discovery platform with B-cell Select™ technology to optimize therapeutic selection and accelerate lead development. Work has already commenced, utilizing IPA's proprietary platforms including LENSai™ technology to advance targeted cancer therapeutics development.
ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-powered antibody discovery and development company, has announced the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. The release date has been moved from March 13 to March 28, 2025, with an earnings call scheduled for 10:30 AM Eastern Time on the same day.
The delay is attributed to providing additional time for auditors to complete necessary reviews and audit requirements, specifically focusing on valuation calculations of goodwill and intangible assets. This extension aims to ensure accurate financial data representation and full regulatory compliance.
ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-powered antibody discovery and development company, has scheduled its third quarter fiscal year 2025 financial results announcement and business update for March 13, 2025. The company will release its financial results via press release followed by a conference call and webcast at 10:30 AM ET.
The earnings call will include a management presentation and a Q&A session. Participants can join through various channels including USA/International toll line (+1-646-307-1963) or toll-free numbers (800-715-9871 for USA and Canada) using Conference ID 3224490. A webcast will be available through the company's IR events page.
ImmunoPrecise Antibodies (NASDAQ: IPA) has announced a strategic collaboration with RIBOPRO to enhance therapeutic antibody discovery by combining RIBOPRO's mRNA and lipid nanoparticle (LNP) technologies with IPA's AI-powered discovery capabilities.
The partnership aims to overcome challenges in antigen expression during antibody discovery by utilizing RIBOPRO's expertise in mRNA sequence optimization and LNP-based delivery alongside IPA's advanced B-cell screening, single-cell analysis, and deep-learning AI workflows.
This integration of mRNA immunization into IPA's discovery pipeline is expected to improve antigen presentation and immune responses, potentially accelerating the development of novel therapeutics.
ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-driven biotherapeutic research company, has announced significant leadership changes. Dr. Kamil Isaev, a technology leader with over 30 years of expertise in AI and semiconductor technologies, has joined the Board of Directors. Isaev currently serves as a Venture Partner at ABRT VC, leading their AI Lab and VC Score project, and has previously held key positions at Intel, Dell EMC, and Align Technology.
The company has also appointed Joseph Scheffler as Interim Chief Financial Officer. Scheffler brings over 20 years of experience in financial management, most recently serving as Interim Corporate Controller at Nidec - Kinetek, where he managed consolidated financial reporting for a $400 million global manufacturing firm. Additionally, Chris Buyse has stepped down from the Board of Directors following his tenure during the company's transitional phase.
ImmunoPrecise Antibodies (NASDAQ: IPA) has received approval from Nasdaq Listing Qualifications to transfer its securities from the Nasdaq Global Market to the Nasdaq Capital Market. This strategic move, effective February 21, 2025, grants IPA an additional 180-day compliance period until August 18, 2025, to meet the minimum bid price requirement of $1.00 per share. The transfer allows the company to maintain its Nasdaq listing while continuing to execute its strategic initiatives.
ImmunoPrecise Antibodies (NASDAQ: IPA) has completed two significant financial initiatives: a USD $8.8 million at-the-market (ATM) equity offering program, generating USD $7.0 million in gross proceeds, and the full conversion of its Yorkville Advisors debenture into common shares.
The company strategically utilized the ATM program to reduce capital costs while strengthening its financial position. The full conversion of the Yorkville debenture eliminates near-term debt obligations, further improving IPA's balance sheet.
According to CEO Dr. Jennifer Bath, these developments demonstrate investor confidence in IPA's vision and technology. The enhanced financial position will support the company's growth strategy and advancement of its AI-powered therapeutic discovery platform, LENSai.
ImmunoPrecise Antibodies (NASDAQ: IPA) has developed a new class of GLP-1 therapies using artificial intelligence through its proprietary LENSai™ platform. The AI-designed therapeutics aim to improve current diabetes and obesity treatments by enhancing efficacy, safety, and patient satisfaction.
The company's innovation focuses on creating GLP-1-like alternatives with potential advantages including increased patentability, extended stability, improved administration routes, reduced dosing requirements, and more efficient manufacturing methods. IPA is exploring transdermal delivery as a non-invasive alternative to injections.
In just two weeks, LENSai generated and optimized novel genetic sequences for GLP-1-like constructs. The company is collaborating with Aldevron, to optimize its alternatives for nucleic acid-based expression systems. The AI-driven approach incorporates optimized genetic elements to explore long-term, stable therapeutic production within the body during pre-clinical investigations.
ImmunoPrecise Antibodies (NASDAQ: IPA) has unveiled its AI-powered pipeline for therapeutic development, marking a strategic shift in drug discovery. The company's approach combines artificial intelligence with first-principles thinking through their proprietary LENSai platform, which organizes biological datasets into a unified framework.
The new pipeline aims to break away from traditional drug discovery methods by deconstructing challenges to their fundamentals and rebuilding processes from scratch. This system integrates computational insights with laboratory validation, focusing on delivering treatments that are both innovative and reliable.
According to CEO Dr. Jennifer Bath, this AI-powered pipeline represents a significant advancement for IPA, fundamentally changing the possibilities in therapeutic development. The initiative focuses on addressing complex therapeutic challenges and pressing medical needs, positioning IPA at the forefront of AI-driven drug discovery.
FAQ
What is the current stock price of Immunoprecise (IPA)?
What is the market cap of Immunoprecise (IPA)?
